However, a key finding emerging from this study is that the antifibrotic efficacy of PDGFR and TGFBR1 tyrosine kinase inhibitors was dependent upon the factor driving the fibrosis, and this could explain why it has been so difficult to develop liver fibrosis therapies. This evidence concerns the gene PDGFRB and Hepatic fibrosis.